[go: up one dir, main page]

MX2016016895A - Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi) bencilamina para el tratamiento de alzhéimer. - Google Patents

Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi) bencilamina para el tratamiento de alzhéimer.

Info

Publication number
MX2016016895A
MX2016016895A MX2016016895A MX2016016895A MX2016016895A MX 2016016895 A MX2016016895 A MX 2016016895A MX 2016016895 A MX2016016895 A MX 2016016895A MX 2016016895 A MX2016016895 A MX 2016016895A MX 2016016895 A MX2016016895 A MX 2016016895A
Authority
MX
Mexico
Prior art keywords
indol
fluoro
ethyl
tetrafluoropropoxy
alzheimer
Prior art date
Application number
MX2016016895A
Other languages
English (en)
Other versions
MX377013B (es
Inventor
Lopez De Diego Heidi
Harold Rock Michael
Birklund Andersen Kristine
Dennis Therkelsen Frans
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58794010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016016895(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MX2016016895A publication Critical patent/MX2016016895A/es
Publication of MX377013B publication Critical patent/MX377013B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a una forma polimórfica novedosa del clorhidrato de N-[2-(6-fluoro-1H-indol-3-il)etil]-3-(2,2,3,3-t etrafluoropropoxi) bencilamina.
MX2016016895A 2014-07-04 2015-07-03 Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina para el tratamiento de alzhéimer. MX377013B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201400369 2014-07-04
PCT/EP2015/065176 WO2016001398A1 (en) 2014-07-04 2015-07-03 Novel polymorphic form of n-[2-(6-fluoro-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer's

Publications (2)

Publication Number Publication Date
MX2016016895A true MX2016016895A (es) 2017-04-27
MX377013B MX377013B (es) 2025-03-07

Family

ID=58794010

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016895A MX377013B (es) 2014-07-04 2015-07-03 Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina para el tratamiento de alzhéimer.

Country Status (42)

Country Link
US (1) US10071963B2 (es)
EP (1) EP3164385B1 (es)
JP (2) JP6643330B2 (es)
KR (1) KR102399374B1 (es)
CN (3) CN112961095A (es)
AP (1) AP2016009643A0 (es)
AR (1) AR101109A1 (es)
AU (1) AU2015282909B2 (es)
CA (1) CA2951794C (es)
CL (1) CL2017000002A1 (es)
CO (1) CO2017000019A2 (es)
CR (1) CR20160605A (es)
CY (1) CY1124594T1 (es)
DK (1) DK3164385T3 (es)
DO (1) DOP2017000001A (es)
EA (1) EA035894B1 (es)
EC (1) ECSP17000222A (es)
ES (1) ES2893619T3 (es)
GE (2) GEAP202114363A (es)
HR (1) HRP20211596T8 (es)
HU (1) HUE056368T2 (es)
IL (1) IL249428B (es)
JO (1) JO3639B1 (es)
LT (1) LT3164385T (es)
MA (1) MA40345B1 (es)
MX (1) MX377013B (es)
MY (1) MY190715A (es)
NZ (1) NZ727251A (es)
PE (1) PE20170522A1 (es)
PH (1) PH12016502477B1 (es)
PL (1) PL3164385T3 (es)
PT (1) PT3164385T (es)
RS (1) RS62380B1 (es)
RU (1) RU2016151637A (es)
SG (1) SG11201610334XA (es)
SI (1) SI3164385T1 (es)
SM (1) SMT202100575T1 (es)
SV (1) SV2016005353A (es)
TN (1) TN2016000549A1 (es)
TW (1) TWI665188B (es)
UA (1) UA121547C2 (es)
WO (1) WO2016001398A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3333154A1 (en) 2016-12-07 2018-06-13 Sandoz Ag Crystalline form of a selective 5-ht6 receptor antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2566056T3 (es) * 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
TW201139370A (en) * 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
CN105175307A (zh) 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途

Also Published As

Publication number Publication date
LT3164385T (lt) 2021-10-11
CN112961094A (zh) 2021-06-15
TN2016000549A1 (en) 2018-04-04
MX377013B (es) 2025-03-07
HRP20211596T8 (hr) 2022-03-04
RU2016151637A3 (es) 2019-01-28
MA40345A (fr) 2021-04-28
CY1124594T1 (el) 2022-07-22
MA40345B1 (fr) 2021-10-29
IL249428A0 (en) 2017-02-28
RU2016151637A (ru) 2018-08-08
SMT202100575T1 (it) 2021-11-12
PT3164385T (pt) 2021-10-07
PH12016502477A1 (en) 2017-04-10
PH12016502477B1 (en) 2017-04-10
CL2017000002A1 (es) 2017-06-23
HUE056368T2 (hu) 2022-02-28
DK3164385T3 (da) 2021-10-11
KR20170023019A (ko) 2017-03-02
SG11201610334XA (en) 2017-01-27
UA121547C2 (uk) 2020-06-25
EP3164385A1 (en) 2017-05-10
ES2893619T3 (es) 2022-02-09
US20170152227A1 (en) 2017-06-01
AP2016009643A0 (en) 2016-12-31
KR102399374B1 (ko) 2022-05-17
US10071963B2 (en) 2018-09-11
EP3164385B1 (en) 2021-09-08
AR101109A1 (es) 2016-11-23
MY190715A (en) 2022-05-12
HRP20211596T1 (hr) 2022-01-07
JP6643330B2 (ja) 2020-02-12
CA2951794C (en) 2023-03-07
CN106458889A (zh) 2017-02-22
SI3164385T1 (sl) 2021-10-29
TWI665188B (zh) 2019-07-11
TW201625525A (zh) 2016-07-16
GEAP202114363A (en) 2021-12-10
GEP20227368B (en) 2022-03-25
CO2017000019A2 (es) 2017-05-31
EA201692485A1 (ru) 2017-05-31
PE20170522A1 (es) 2017-05-28
ECSP17000222A (es) 2017-02-24
JO3639B1 (ar) 2020-08-27
JP2020059724A (ja) 2020-04-16
WO2016001398A1 (en) 2016-01-07
SV2016005353A (es) 2017-03-23
BR112017000127A2 (pt) 2018-01-23
EA035894B1 (ru) 2020-08-27
NZ727251A (en) 2023-06-30
DOP2017000001A (es) 2017-03-31
JP2017519829A (ja) 2017-07-20
RS62380B1 (sr) 2021-10-29
PL3164385T3 (pl) 2021-12-20
CA2951794A1 (en) 2016-01-07
CN112961095A (zh) 2021-06-15
AU2015282909A1 (en) 2017-01-05
AU2015282909B2 (en) 2019-02-07
IL249428B (en) 2019-10-31
CR20160605A (es) 2017-04-24

Similar Documents

Publication Publication Date Title
EA201790271A1 (ru) Ингибиторы гликозидазы
IL246875A0 (en) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for the treatment of Alzheimer's disease
DK3463351T3 (da) Behandling til parkinsons sygdom
LT3413870T (lt) Igmesinas, skirtas panaudoti alzheimerio ligos gydymui
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
MX2016016895A (es) Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi) bencilamina para el tratamiento de alzhéimer.
ME03056B (me) Jedinjenja 3,4-diamino-6-hloropirazin-2-karboksamida za tretman bolesti posredovanih sa enac
EP3529243C0 (en) (Z)-3-(2-(5-BROMO-1H-INDOLE-3-YL)-2-CYANOVINYL)-4-METHOXYBENZONITRILE FOR THE TREATMENT OF ENDOMETRIOSIS
SI3148588T1 (sl) N,N-bis-2-merkaptoetil izoftalamid za zdravljenje Parkinsonove bolezni
TH1601002537A (th) กระบวนการสำหรับการสังเคราะห์สารยับยั้งอินโดลเอมีน 2,3-ไดออกซีจีเนสชนิดหนึ่ง
UA96409U (uk) Спосіб реабілітації жінок після перенесеного сальпінгоофориту

Legal Events

Date Code Title Description
FG Grant or registration